ClinicalTrials.gg
CompletedNCT03463135Updated Apr 25, 2022

A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients

A Phase 1 interventional study of Glucopyranosyl Lipid A (GLA) and Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) in Food Allergy, sponsored by Sanofi. Completed at 16 sites in United States. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2019, 7 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
12 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 139 studies in Food Hypersensitivity with a site in United States — 19 open to participants now, 28 under way, 3 of them phase 3. Food Hypersensitivity · United States.

Enrollment
71st of 105
27 · median 41
Started
2018
with 5 others
Phase 1
18 of 139
1 open now
Registered
83rd of 139
by date

Among the 139 studies in Food Hypersensitivity with a site in United States, this one is the 71st largest by enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2018, is one of 18 in phase 1, and was the 83rd registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

19 of the 139 studies in Food Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 40 (77%) stop at 75 or younger; 44 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Food Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

To assess tolerability and safety of SAR439794 [peanut extract (PE) sublingual immunotherapy (SLIT) adjuvanted with Glucopyranosyl Lipid A (GLA)] after repeated sublingual (SL) daily administration in peanut allergic adult and adolescent patients.

Secondary Objective:

To assess pharmacodynamics of SAR439794 after repeated SL daily administration in peanut allergic adult and adolescent patients.

Read the detailed description

The total study duration per participant is approximately from 15 to 18 weeks (core study) from screening until end-of-study visit, and 2 phone calls at Week 26 and Week 52 after the last Investigational Medicinal Product (IMP) dose.

03

Conditions studied

  • Food Allergy

Browse trials for

04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, between 18 and 55 years of age, inclusive and adolescents between 12 and 17 years of age (after enrollment of 20 adult patients completed the 6 weeks dose escalation period and the safety and tolerability is deemed acceptable).
  • Physician-diagnosed peanut allergy OR convincing history of objective clinical symptoms consistent with immediate within 4 hours following known ingestion of peanuts or peanut-containing food AND by the following combined criteria:
  • Peanut-specific IgE (P-sIgE) >5 kUA/L and Arah2-specific IgE (Arah2-sIgE) >2 kUA/L,
  • Skin Prick Test (SPT) to peanut allergen ≥5 mm compared to saline control.
  • High-sensitivity C reactive protein (hs-CRP), fibrinogen and within laboratory normal range unless the Investigator considers an abnormality to be clinically irrelevant.
  • Ability to perform spirometry based on the American Thoracic Society guidelines.
  • Patient must be trained on the proper use of an injectable epinephrine device and should be able to use it.

Exclusion criteria

Exclusion criteria:

  • Any history or presence of , cardiovascular disease, chronic lung disease, , psychiatric illness, or gastrointestinal inflammatory conditions, including celiac disease, inflammatory bowel disease and eosinophilic gastrointestinal disorders.
  • History of severe anaphylaxis, documented hypotension, neurological compromise (confusion, loss of consciousness), or incontinence known or suspected to be caused by ingestion of peanut or that required treatment with 2 or more administrations of epinephrine or hospitalization.
  • Daily oral use for >1 month during the past year, burst oral steroid course in the past 6 months, or >1 burst oral steroid course in the past year.
  • Asthma requiring >1 hospitalization in the past year or >1 emergency department visit in the past 6 months.
  • Severe or poorly controlled atopic dermatitis.
  • Diagnosis of eosinophilic esophagitis.
  • Diagnosis of other severe or complicating medical problems.
  • Primary immune deficiency.
  • If female, pregnancy (defined as positive β-HCG [human chorionic gonadotropin] blood test), breastfeeding.
  • If female of , unable to use an effective method of to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
  • Use of beta blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or monoamine oxidase inhibitors.
  • Any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  • Any patient who cannot be contacted in case of emergency.
  • Any patient who is the Investigator or any subinvestigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
  • Positive result on any of the following tests: surface (HBs Ag) antigen, anti-hepatitis B virus core antibodies (anti-HBc Ab), anti- virus antibodies (anti-HCV Ab), anti- 1 and 2 antibodies (anti-HIV1 and anti- HIV2 Ab).
  • Presence of sublingual epithelium and oral mucosa wound or infection (abcess, ulcer, candidiasis, gingivitis, etc.) or painful tooth decay.
  • Participation in any food immunotherapy interventional study within the past 6 months.
  • Patients who had received any monophosphoryl lipid (MPL)- or glucopyranosyl lipid A (GLA)-containing products within the last 6 months.
  • Patients who experienced a Grade 3 or higher treatment emergent adverse event following administration of a MPL- or GLA-containing product.
  • Use within the past 6 months of systemic immunomodulatory treatment and biologics with an immune target, including Xolair®.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    SAR439794 [PE SLIT + GLA)]

    GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks

    Drug: Glucopyranosyl Lipid A (GLA) · Drug: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)

  • Experimental
    Placebo for GLA + SLIT PE

    Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks

    Drug: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) · Drug: Placebo for GLA

  • Placebo comparator
    Placebo for GLA + Placebo for SLIT PE

    Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks

    Drug: Placebo for GLA · Drug: Placebo for SLIT PE

Interventions

  • DrugGlucopyranosyl Lipid A (GLA)

    Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual

  • DrugSublingual Immuno Therapy (SLIT) Peanut Extract (PE)

    Pharmaceutical form:Solution Route of administration: Sublingual

  • DrugPlacebo for GLA

    Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual

  • DrugPlacebo for SLIT PE

    Pharmaceutical form:Solution Route of administration: Sublingual

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Number of participants with AEs

    Time frame: Up to Week 52

Secondary outcomes

  1. Assessment of pharmacodynamic (PD) parameter: Peanut-specific serum Immunoglobulin G (IgG) levels

    Change from baseline to Day 85 in peanut-specific serum IgGs levels in patients administered with Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy Peanut Extract (SLIT PE) versus placebo for GLA + SLIT PE

    Time frame: Baseline to Day 85

  2. Assessment of PD parameter: Peanut-specific serum IgG levels

    Change from baseline to Day 57 in peanut-specific serum IgGs levels (total P-sIgGs, P-sIgG4 and P-sIgG1) in patients administered with GLA + SLIT PE versus placebo for GLA + SLIT PE

    Time frame: Baseline to Day 57

  3. Assessment of PD parameter: Peanut-specific serum Immunoglobulin E (IgE) levels

    Change from baseline to Day 57 and Day 85 in peanut-specific IgE in patients administered with GLA + SLIT PE versus placebo for GLA + SLIT PE

    Time frame: Baseline to Day 57, Baseline to Day 85

  4. Assessment of PD parameter: Skin Prick Test

    Absolute change from baseline in Skin Prick Test (SPT) to peanut allergen at Day 85 only in patients administered with GLA + SLIT PE versus placebo for GLA + SLIT PE

    Time frame: On Day 85

  5. Maximum SLIT PE dose

    Maximum SLIT PE dose reached by patients administered with GLA + SLIT PE versus placebo GLA + SLIT PE

    Time frame: On Day 85

07

Study locations

16 sites
  • Investigational Site Number 8400004
    Little Rock, Arkansas 72202, United States
  • Investigational Site Number 8400019
    Mission Viejo, California 92691, United States
  • Investigational Site Number 8400008
    San Diego, California 92123, United States
  • Investigational Site Number 8400020
    San Jose, California 95117, United States
  • Investigational Site Number 8400006
    Stanford, California 94305, United States
  • Investigational Site Number 8400013
    Denver, Colorado 80230, United States
  • Investigational Site Number 8400014
    Louisville, Kentucky 40215, United States
  • Investigational Site Number 8400002
    Baltimore, Maryland 21287, United States
  • Investigational Site Number 8400001
    Boston, Massachusetts 02114, United States
  • Investigational Site Number 8400009
    Minneapolis, Minnesota 55402, United States
  • Investigational Site Number 8400016
    Minneapolis, Minnesota 55402, United States
  • Investigational Site Number 8400010
    Charleston, North Carolina 29420, United States
  • Investigational Site Number 8400011
    Cincinnati, Ohio 45229, United States
  • Investigational Site Number 8400012
    Medford, Oregon 97504, United States
  • Investigational Site Number 8400003
    Seattle, Washington 98105, United States
  • Investigational Site Number 8400017
    Madison, Wisconsin 53792, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in May 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Mar 13, 2018
StartActual
May 7, 2018
Primary completionActual
May 8, 2019
CompletionActual
Mar 10, 2020
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03463135
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 13, 2018
Start date
May 7, 2018
Primary completion
May 8, 2019
Completion
Mar 10, 2020
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion